FORENSIC TOXICOLOGY REPORT



FAA Civil Aerospace Medical Institute Bioaeronautical Sciences Research Branch, Forensic Sciences P.O. Box 25082, Oklahoma City, Oklahoma 73125 Ph: 405-954-6254, Fax: 405-954-3705



December 11, 2019

NAME	Pilot	CAMI #	201900246001	NTSB #	ERA20FA022
LOCATION	Ocala, FL	MODE	Aviation	N# 959	CM
DATE OF AC	CIDENT 10/31/2019	DATE RE	CEIVED 11/6/2019	STATUS	FATAL

SPECIMENS Brain, Gastric, Heart, Kidney, Liver, Lung, Muscle, Spleen

PUTREFACTION No

Screening tests employed

Muscle - Volatiles (HS GC/FID) Brain - Volatiles (HS GC/FID) Liver - Drugs of abuse (Immunoassay) Liver - General drug screen (LC/MS, GC/MS)

Analyte	<u>Result</u>	<u>Specimen</u>	<u>Instrument</u>
Ethanol	Not Detected	Muscle	HSGC/FID
Ethanol	Not Detected	Brain	HSGC/FID
Diazepam	Detected	Liver	LC/MS
Diazepam	Detected	Muscle	LC/MS
Nordiazepam	Detected	Liver	LC/MS
Nordiazepam	Detected	Muscle	LC/MS
Oxazepam	Detected	Liver	LC/MS
Oxazepam	Detected	Muscle	LC/MS
Valsartan	Detected	Liver	LC/MS
Valsartan	Detected	Muscle	LC/MS

Russell Lewis, Ph.D., F-ABFT Supervisor, Forensic Sciences Bioaeronautical Sci. Research Lab CAMI, FAA c=US, o=U.S. Government, ou=AMC, ou=AMC, cn=RUSSELL J LEWIS 2019.12.11 15:55:34 -06'00'

This record may be releasable under the FOIA request 15 days after signature date, unless FOIA exemptions apply. Results listed in this report relate to tested specimen(s) only. See Forensic Toxicology web site for testing methodology and cutoffs as well as drug, FOIA, and contact information. http://www.faa.gov/go/toxlab



NMS Labs

CONFIDENTIAL

200 Weish Road, Horsham, PA 19044-2208

Phone: e-mail:

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Toxicology Report	Patient Name	
Report Issued 11/20/2019 17:23	Patient ID 2019-202 Chain 19341183	1
To: 10810 Medical Examiner's Office - District 5 Attn: Dr. Barbara C. Wolf	Age 73 Y DOB Gender Male Workorder 1934118	3
Leesburg, FL 34748	Page 1 of 4	

Positive Findings:

Compound	Result	Units	Matrix Source	
Diazepam	96	ng/mL	001 - Chest Blood	
Nordiazepam	94	ng/mL	001 - Chest Blood	
Delta-9 THC	0.69	ng/mL	001 - Chest Blood	

See Detailed Findings section for additional information

Testing Requested:

Analysis Code	Description	
1002B	Carbon Monoxide Exposure Biouptake Screen, Blood	
8051B	Postmortem, Basic, Blood (Forensic)	

Specimens Received:

ID	Tube/Container	Volume/ Mass	Collection Date/Time	Matrix Source	Miscellaneous Information
001	Gray Top Tube	6.5 mL	11/01/2019 10:00	Chest Blood	
002	Gray Top Tube	8.75 mL	11/01/2019 10:00	Chest Blood	
003	Red Top Tube	1 mL	11/01/2019 10:00	Vitreous Fluid	

All sample volumes/weights are approximations.

Specimens received on 11/06/2019.



CONFIDENTIAL



Chain 19341183 Patient ID 2019-2021

19341183

Page 2 of 4

Workorder

Detailed Findings:

Analysis and Comments	Result	Units	Rpt. Limit	Specimen Source	Analysis By
Diazepam	96	ng/mL	20	001 - Chest Blood	LC-MS/MS
Nordiazepam	94	ng/mL	20	001 - Chest Blood	LC-MS/MS
Delta-9 THC	0.69	ng/mL	0.50	001 - Chest Blood	LC-MS/MS

Other than the above findings, examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.

Reference Comments:

1. Delta-9 THC (Active Ingredient of Marijuana) - Chest Blood:

Marijuana is a DEA Schedule I hallucinogen. Pharmacologically, it has depressant and reality distorting effects. Collectively, the chemical compounds that comprise marijuana are known as Cannabinoids.

Delta-9-THC is the principle psychoactive ingredient of marijuana/hashish. It rapidly leaves the blood, even during smoking, falling to below detectable levels within several hours. Delta-9-carboxy-THC (THCC) is the inactive metabolite of THC and may be detected for up to one day or more in blood. Both delta-9-THC and THCC may be present substantially longer in chronic users.

THC concentrations in blood are usually about one-half of serum/plasma concentrations. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.

Diazepam (Valium®) - Chest Blood:

Diazepam is a benzodiazepine used primarily for its sedative anxiolytic or muscle relaxing effects. It is a U.S. DEA Schedule IV listed central nervous system depressant, and patients using this medication are warned accordingly, especially concerning motor functions. It is habituating, and frequently abused. It is metabolized to several pharmacologically active compounds: nordiazepam, oxazepam and temazepam. In order to evaluate the effects of this compound, concentrations of these metabolites must also be considered.

The reported diazepam concentration in a chronic steady-state regimen of 5 mg twice daily ranges from 100 - 400 ng/mL with nordiazepam being in the range of 130 - 500 ng/mL. Oxazepam and temazepam may be present in low concentrations.

Toxic effects may be produced by blood concentrations in excess of 1500 ng/mL; fatalities produced by diazepam alone are rare, but may occur at blood concentrations greater than 5000 ng/mL. Alcohol greatly enhances the activity of the benzodiazepines.

3. Nordiazepam (Chlordiazepoxide Metabolite) - Chest Blood:

Nordiazepam is a pharmacologically active metabolite of several benzodiazepines, including diazepam (Valium®) and chlordiazepoxide (Librium®). The action of this compound is based on its central nervous system depressant activity. Nordiazepam has a very long elimination half-life and may be identified long after the parent drug has been completely eliminated from the circulation.

Psychiatric patients taking chronic diazepam doses ranging from 2 to 55 mg daily had steady state plasma concentrations of nordiazepam averaging 390 ng/mL (range 26 to 1600 ng/mL). Chronic therapy with a daily oral dose of 22.5 mg clorazepate produced reported steady-state plasma concentrations of nordiazepam of 660 +/- 140 ng/mL. The active metabolites oxazepam and temazepam may be present in low concentrations. The blood to plasma ratio of nordiazepam is 0.6.

A fatal case was reported with a nordiazepam blood concentration of 5500 ng/mL along with 0.180 g/dL ethanol and 7000 ng/mL chlordiazepoxide. Alcohol greatly enhances the activity of the benzodiazepines.

Unless alternate arrangements are made by you, the remainder of the submitted specimens will be discarded two (2) years from the date of this report; and generated data will be discarded five (5) years from the date the analyses were performed.

RECEIVED NOV 2 0 2019

NMS v.18.0

CONFIDENTIAL



 Workorder
 19341183

 Chain
 19341183

 Patient ID
 2019-2021

Page 3 of 4

Workorder 19341183 was electronically signed on 11/20/2019 15:42 by:

Jennifer L. Turri Swatek, M.S.F.S., D-ABFT-FT Certifying Scientist

Analysis Summary and Reporting Limits:

All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.

Acode 1002B - Carbon Monoxide Exposure Biouptake Screen, Blood - Chest Blood

-Analysis by Spectrophotometry (SP) for:

Compound	Rpt. Limit	Compound	Rot. Limit
Carboxyhemoglobin	5 %Saturation		
Acode 50012B - Benzodiazepines	Confirmation, Blood - Ches	st Blood	

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
7-Amino Clonazepam	5.0 ng/mL	Flurazepam	2.0 ng/mL
Alpha-Hydroxyalprazolam	5.0 ng/mL	Hydroxyethylflurazepam	5.0 ng/mL
Alprazolam	5.0 ng/mL	Hydroxytriazolam	5.0 ng/mL
Chlordiazepoxide	20 ng/mL	Lorazepam	5.0 ng/mL
Clobazam	20 ng/mL	Midazolam	5.0 ng/mL
Clonazepam	2.0 ng/mL	Nordiazepam	20 ng/mL
Desalkylflurazepam	5.0 ng/mL	Oxazepam	20 ng/mL
Diazepam	20 ng/mL	Temazepam	20 ng/mL
Estazolam	5.0 ng/mL	Triazolam	2.0 ng/mL

Acode 52198B - Cannabinoids Confirmation, Blood - Chest Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
11-Hydroxy Delta-9 THC	1.0 ng/mL	Delta-9 THC	0.50 ng/mL
Delta-9 Carboxy THC	5.0 ng/mL		

Acode 8051B - Postmortem, Basic, Blood (Forensic) - Chest Blood

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

Compound	Rot. Limit	Compound	Rot. Limit
Amphetamines	20 ng/mL	Fentanyl / Acetyl Fentanyl	0.50 ng/mL
Barbiturates	0.040 mcg/mL	Methadone / Metabolite	25 ng/mL
Benzodiazepines	100 ng/mL	Methamphetamine / MDMA	20 ng/mL
Buprenorphine / Metabolite	0.50 ng/mL	Opiates	20 ng/mL
Cannabinoids	10 ng/mL	Oxycodone / Oxymorphone	10 ng/mL
Cocaine / Metabolites	20 ng/mL	Phencyclidine	10 ng/mL

-Analysis by Headspace Gas Chromatography (GC) for:

RECEIVED NOV 2 0 2019

CONFIDENTIAL



 Workorder
 19341183

 Chain
 19341183

 Patient ID
 2019-2021

Page 4 of 4

Analysis Summary and Reporting Limits:

Compound	Rpt. Limit	Compound	Rpt. Limit
Acetone	5.0 mg/dL	Isopropanol	5.0 mg/dL
Ethanol	10 mg/dL	Methanol	5.0 mg/dL

RECEIVED NOV 2 0 2019

FORENSIC TOXICOLOGY REPORT



FAA Civil Aerospace Medical Institute Bioaeronautical Sciences Research Branch, Forensic Sciences P.O. Box 25082, Oklahoma City, Oklahoma 73125 Ph: 405-954-6254, Fax: 405-954-3705



December 11, 2019

NAME A	A&P Mechanic/Pax	CAMI #	201900246002	NTSB #	ERA20FA022
LOCATION (Ocala, FL	MODE	Aviation	N# 959	9CM
DATE OF AC	CIDENT 10/31/2019	DATE RE	ECEIVED 11/6/2019	STATUS	FATAL

SPECIMENS Blood (Cavity), Brain, Gastric, Heart, Kidney, Liver, Lung, Muscle, Urine, Vitreous

PUTREFACTION No

Screening tests employed

Blood (Cavity) - Carboxyhemoglobin (UV/VIS) Blood (Cavity) - Volatiles (HS GC/FID) Vitreous - Glucose (Chemical Analyzer) Urine - Glucose (Chemical Analyzer) Urine - Drugs of abuse (Immunoassay) Urine - General drug screen (LC/MS, GC/MS)

Analyte	Result	<u>Specimen</u>	<u>Instrument</u>
Carboxyhemoglobin	Not Detected	Blood (Cavity)	UV/VIS
Ethanol	Not Detected	Blood (Cavity)	HSGC/FID
Glucose	15 (mg/dL)	Vitreous	Analyzer
Glucose	8 (mg/dL)	Urine	Analyzer
Loratadine	Detected	Blood (Cavity)	LC/MS
Loratadine	Negative	Urine	LC/MS
Desloratadine	Detected	Blood (Cavity)	LC/MS
Desloratadine	Detected	Urine	LC/MS
Ibuprofen	Detected	Blood (Cavity)	LC/MS
Ibuprofen	Detected	Urine	LC/MS



c=US, o=U.S. Government, ou=AMC, ou=AMC, cn=RUSSELL J LEWIS 2019.12.18 14:41:59 -06'00'

Russell Lewis, Ph.D., F-ABFT Supervisor, Forensic Sciences Bioaeronautical Sci. Research Lab CAMI, FAA

This record may be releasable under the FOIA request 15 days after signature date, unless FOIA exemptions apply. Results listed in this report relate to tested specimen(s) only. See Forensic Toxicology web site for testing methodology and cutoffs as well as drug, FOIA, and contact information. http://www.faa.gov/go/toxlab